NASDAQ
20.02.25
18:41 Uhr
1,740 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.01. | BeyondSpring sells stake in preferred shares of SEED Therapeutics for ~$35.4M | 1 | Seeking Alpha | ||
| 28.01. | BeyondSpring sells SEED Therapeutics shares for $35.4M | 2 | Investing.com | ||
| 28.01. | BeyondSpring, Inc.: BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies | 2 | GlobeNewswire (USA) | ||
| 28.01. | BeyondSpring Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.01. | BeyondSpring Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11.24 | BeyondSpring, Inc.: BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior ... | 120 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
| 16.09.24 | BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC | 4 | Seeking Alpha | ||
| 16.09.24 | BeyondSpring berichtet über sicherere Therapieoption für NSCLC | 1 | Investing.com Deutsch | ||
| 16.09.24 | BeyondSpring reports safer NSCLC therapy option | 10 | Investing.com | ||
| 16.09.24 | BeyondSpring reports promising phase 2 NSCLC study results | 10 | Investing.com | ||
| 16.09.24 | BeyondSpring, Inc.: BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 | 160 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| 16.09.24 | BeyondSpring, Inc.: BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 | 143 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| 03.09.24 | BeyondSpring, Inc.: BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin | 1 | GlobeNewswire (USA) | ||
| 29.08.24 | BeyondSpring Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.08.24 | BeyondSpring, Inc.: SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications | 195 | GlobeNewswire (Europe) | The SEED-Eisai Research Collaboration leverages Eisai's leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to $1.5 billion plus tiered... ► Artikel lesen | |
| 29.04.24 | BeyondSpring, Inc.: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results | 205 | GlobeNewswire (Europe) | - BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism... ► Artikel lesen | |
| 25.03.24 | BeyondSpring, Inc.: BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer | 102 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 68,13 | -11,20 % | Tempus AI Aktie: Langfristige Planung vorgestellt | Der Technologiekonzern Tempus AI verzeichnet derzeit bemerkenswerte Bewegungen im Aktienhandel, wobei mehrere hochrangige Führungskräfte in der vergangenen Woche umfangreiche Aktienverkäufe tätigten.... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 34,560 | -0,95 % | Harmony Biosciences price target cut to $42 at Mizuho | ||
| ARVINAS | 17,770 | -3,27 % | Arvinas Inc.: Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | - Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 - - Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,010 | 0,00 % | Dyne Therapeutics SVP Richard Scalzo verkauft Aktien im Wert von 34.707 US-Dollar | ||
| RECURSION PHARMACEUTICALS | 9,265 | -10,48 % | Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025? | ||
| SPRINGWORKS THERAPEUTICS | 58,24 | -2,77 % | Merck KGaA: Wechsel im Top-Management - wann schlägt der DAX-Konzern bei SpringWorks zu? | Die Aktie von Merck KGaA notiert weiterhin in der Nähe des 52-Wochen-Tiefs. Das bestätigte Übernahmeinteresse an SprinWorks Therapeutics hat den DAX-Wert jüngst unter Druck gesetzt, denn die Marktteilnehmer... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 36,810 | -1,58 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,430 | +1,76 % | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
| DISC MEDICINE | 54,53 | +0,33 % | Disc Medicine Inc: Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission | Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing... ► Artikel lesen | |
| ABSCI | 4,960 | -4,43 % | Absci Corporation: Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery | VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,440 | -8,15 % | Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025 | ||
| SUMMIT THERAPEUTICS | 22,090 | -4,21 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
| OSR HOLDINGS | 4,280 | +24,06 % | Pre-market Movers: Sintx Technologies, Cycurion, OSR Holdings, ReShape Lifesciences, NewGenIvf Group | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.35 A.M. ET).In the Green Sintx Technologies, Inc. (SINT) is up over 87%... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 42,330 | +0,57 % | MoonLake Immunotherapeutics AG: MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody sonelokimab | New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 31,080 | -4,46 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen |
BEYONDSPRING INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,740 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.
